Genfit

GNFT · Euronext Paris

Public Market Listing

GNFTEuronext Paris

Euronext Paris primary exchange listing

Live quotes, historical charts, and market capitalization for Genfit are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Elafibranor(Iqirvo)
Approved
PPAR-alpha/PPAR-deltaSmall molecule
Cholestatic Liver Disease
Primary Biliary Cholangitis
Phase 1/2
PPT1 (palmitoyl-protein thioesterase 1)Small molecule
Biliary Tract Cancer
Cholangiocarcinoma with KRAS Mutation

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Elafibranor · IqirvoPhase 3Primary Biliary Cholangitis
Est. primary completion 2026-12-17 · NCT06730061 · CT.gov ↗
What to watch
2027 (1)
December 2027 (1)
EzurpimtrostatPhase 1/2Cholangiocarcinoma
Est. primary completion 2027-12 · NCT05874414 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Elafibranor · IqirvoPhase 3Primary Biliary Cholangitis (PBC)
Est. primary completion 2029-05-31 · NCT06016842 · CT.gov ↗
What to watch
2031 (2)
April 2031 (1)
Elafibranor · IqirvoPhase 3Primary Sclerosing Cholangitis
Est. primary completion 2031-04-30 · NCT07387549 · CT.gov ↗
What to watch
September 2031 (1)
Elafibranor · IqirvoPhase 2Primary Sclerosing Cholangitis
Est. primary completion 2031-09-23 · NCT05627362 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 July 2026Topline resultElafibranorELSPIRE phase IIIb topline
Ipsen · Source ↗

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$74M$117M$119M$97Mreport ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$73M$51M$85M—report ↗
2023-FY$31M$50M$86M$31Mreport ↗